Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000)
PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) is a global surveillance study established in 1999 to monitor antibacterial resistance of respiratory tract organisms. Thirteen centers from Argentina, Brazil and Mexico participat ed during 1999-2000;...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
|
Series: | Brazilian Journal of Infectious Diseases |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702003000100006&lng=en&tlng=en |
id |
doaj-f59c18588e334a6a92b8b3717341e87f |
---|---|
record_format |
Article |
spelling |
doaj-f59c18588e334a6a92b8b3717341e87f2020-11-25T02:58:17ZengElsevierBrazilian Journal of Infectious Diseases1678-439171446110.1590/S1413-86702003000100006S1413-86702003000100006Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000)C. Mendes0M. E. Marin1F. Quiñones2J. Sifuentes-Osornio3C. Cuilty Siller4M. Castanheira5C. M. Zoccoli6H. López7A. Súcari8F. Rossi9G. Barriga Angulo10A.J.A. SeguraC. Starling11I. Mimica12D. Felmingham13Fleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicinePROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) is a global surveillance study established in 1999 to monitor antibacterial resistance of respiratory tract organisms. Thirteen centers from Argentina, Brazil and Mexico participat ed during 1999-2000; they collected 1,806 isolates (Streptococcus pneumoniae 518, Haemophilus influenzae 520, Moraxella catarrhalis 140, Staphylococcus aureus 351, S. pyogenes 277). Overall, 218 (42.1%) of the S. pneumoniae isolates had reduced susceptibility to penicillin, 79 (15.3%) were penicillin-resistant and 79 (15.3%) were erythromycin-resistant. Mexico had the highest prevalence of penicillin (76.5%) and erythromycin (31.2%) resistance. Of 77 erythromycin-resistant S. pneumoniae tested for resistance genotype, 43 possessed mef(A), 33 possessed erm(B) and 1 possessed both erm(B) and mef(A) mechanism. All S. pneumoniae isolates were fully susceptible to telithromycin, linezolid, teicoplanin and vancomycin. Among H. influenzae isolates, 88 (16.9%) produced b-lactamase, ranging from 11% (Brazil) to 24.5% (Mexico). Among M. catarrhalis isolates, 138 (98.6%) produced b-lactamase. Twenty-four (8.7%) of the S. pyogenes isolates were erythromycin-resistant; resistance being attributable to mefA (n=18), ermTR (n=5) and ermB (n=1). All H. influenzae, M. catarrhalis and S. pyogenes were fully susceptible to telithromycin. Methicillin resistance was found in 26.5% of the S. aureus isolates (Argentina 15%; Mexico 20%; Brazil 31.3%). Telithromycin was effective against 97.7% of methicillin-susceptible isolates. PROTEKT confirms that antibacterial resistance is an emerging problem in Latin America. The previously reported high levels of pneumococcal resistance to the b-lactam and macrolides were exceeded. New agents that do not induce resistance or that exert low selective pressure, e.g. telithromycin, are essential to safeguard future antibacterial efficacy.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702003000100006&lng=en&tlng=enPROTEKTLatin Americaresistancerespiratory tract infectionsStreptococcus pneumoniaeHaemophilus influenzaeMoraxella catarrhalisStreptococcus pyogenesStaphylococcus aureus |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
C. Mendes M. E. Marin F. Quiñones J. Sifuentes-Osornio C. Cuilty Siller M. Castanheira C. M. Zoccoli H. López A. Súcari F. Rossi G. Barriga Angulo A.J.A. Segura C. Starling I. Mimica D. Felmingham |
spellingShingle |
C. Mendes M. E. Marin F. Quiñones J. Sifuentes-Osornio C. Cuilty Siller M. Castanheira C. M. Zoccoli H. López A. Súcari F. Rossi G. Barriga Angulo A.J.A. Segura C. Starling I. Mimica D. Felmingham Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000) Brazilian Journal of Infectious Diseases PROTEKT Latin America resistance respiratory tract infections Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis Streptococcus pyogenes Staphylococcus aureus |
author_facet |
C. Mendes M. E. Marin F. Quiñones J. Sifuentes-Osornio C. Cuilty Siller M. Castanheira C. M. Zoccoli H. López A. Súcari F. Rossi G. Barriga Angulo A.J.A. Segura C. Starling I. Mimica D. Felmingham |
author_sort |
C. Mendes |
title |
Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000) |
title_short |
Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000) |
title_full |
Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000) |
title_fullStr |
Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000) |
title_full_unstemmed |
Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000) |
title_sort |
antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in latin america: results from the protekt surveillance study (1999-2000) |
publisher |
Elsevier |
series |
Brazilian Journal of Infectious Diseases |
issn |
1678-4391 |
description |
PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) is a global surveillance study established in 1999 to monitor antibacterial resistance of respiratory tract organisms. Thirteen centers from Argentina, Brazil and Mexico participat ed during 1999-2000; they collected 1,806 isolates (Streptococcus pneumoniae 518, Haemophilus influenzae 520, Moraxella catarrhalis 140, Staphylococcus aureus 351, S. pyogenes 277). Overall, 218 (42.1%) of the S. pneumoniae isolates had reduced susceptibility to penicillin, 79 (15.3%) were penicillin-resistant and 79 (15.3%) were erythromycin-resistant. Mexico had the highest prevalence of penicillin (76.5%) and erythromycin (31.2%) resistance. Of 77 erythromycin-resistant S. pneumoniae tested for resistance genotype, 43 possessed mef(A), 33 possessed erm(B) and 1 possessed both erm(B) and mef(A) mechanism. All S. pneumoniae isolates were fully susceptible to telithromycin, linezolid, teicoplanin and vancomycin. Among H. influenzae isolates, 88 (16.9%) produced b-lactamase, ranging from 11% (Brazil) to 24.5% (Mexico). Among M. catarrhalis isolates, 138 (98.6%) produced b-lactamase. Twenty-four (8.7%) of the S. pyogenes isolates were erythromycin-resistant; resistance being attributable to mefA (n=18), ermTR (n=5) and ermB (n=1). All H. influenzae, M. catarrhalis and S. pyogenes were fully susceptible to telithromycin. Methicillin resistance was found in 26.5% of the S. aureus isolates (Argentina 15%; Mexico 20%; Brazil 31.3%). Telithromycin was effective against 97.7% of methicillin-susceptible isolates. PROTEKT confirms that antibacterial resistance is an emerging problem in Latin America. The previously reported high levels of pneumococcal resistance to the b-lactam and macrolides were exceeded. New agents that do not induce resistance or that exert low selective pressure, e.g. telithromycin, are essential to safeguard future antibacterial efficacy. |
topic |
PROTEKT Latin America resistance respiratory tract infections Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis Streptococcus pyogenes Staphylococcus aureus |
url |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702003000100006&lng=en&tlng=en |
work_keys_str_mv |
AT cmendes antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000 AT memarin antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000 AT fquinones antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000 AT jsifuentesosornio antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000 AT ccuiltysiller antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000 AT mcastanheira antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000 AT cmzoccoli antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000 AT hlopez antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000 AT asucari antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000 AT frossi antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000 AT gbarrigaangulo antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000 AT ajasegura antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000 AT cstarling antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000 AT imimica antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000 AT dfelmingham antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000 |
_version_ |
1724707365817679872 |